NEW YORK (TheStreet) -- PhotoMedex (PHMD) shares are down -14.1% to $9.29 on Thursday following the release of the company's second quarter financial results.
The global skin health solutions company reported earnings of 1 cent per diluted share, 7 cents short of analysts expectations for the quarter.
Revenue for the quarter fell 10.3% from the previous year to $52.1 million, below analysts expectations of $62.05 million.
TheStreet Ratings team rates PHOTOMEDEX INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
"We rate PHOTOMEDEX INC (PHMD) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income."
Must Read: Warren Buffett's 25 Favorite Stocks
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: PHMD Ratings Report
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.